U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula 2C13H21NO3.C4H6O6
Molecular Weight 628.7083
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 4
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of LEVALBUTEROL TARTRATE

SMILES

O[C@H]([C@@H](O)C(O)=O)C(O)=O.CC(C)(C)NC[C@H](O)C1=CC=C(O)C(CO)=C1.CC(C)(C)NC[C@H](O)C2=CC=C(O)C(CO)=C2

InChI

InChIKey=VNVNZKCCDVFGAP-FPDJQMMJSA-N
InChI=1S/2C13H21NO3.C4H6O6/c2*1-13(2,3)14-7-12(17)9-4-5-11(16)10(6-9)8-15;5-1(3(7)8)2(6)4(9)10/h2*4-6,12,14-17H,7-8H2,1-3H3;1-2,5-6H,(H,7,8)(H,9,10)/t2*12-;1-,2-/m001/s1

HIDE SMILES / InChI

Molecular Formula C4H6O6
Molecular Weight 150.0868
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula C13H21NO3
Molecular Weight 239.3107
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Levalbuterol is the (R)-enantiomer of the drug substance racemic albuterol (salbutamol). Binding studies have demonstrated that (R)-albuterol binds to the beta2-adrenergic receptor with a high affinity, whereas (S)-albuterol binds with 100-fold less affinity than (R)-albuterol. Other evaluations have suggested that (R)-albuterol possesses the bronchodilatory, bronchoprotective, and ciliary-stimulatory properties of racemic albuterol, while (S)-albuterol does not contribute beneficially to the therapeutic effects of the racemate and was originally assumed to be inert. Xopenex (levalbuterol HCl) Inhalation Solution is indicated for the treatment or prevention of bronchospasm in adults, adolescents, and children 6 years of age and older with reversible obstructive airway disease.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
236.0 nM [Kd]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
XOPENEX

Approved Use

XOPENEX (levalbuterol HCl) Inhalation Solution Concentrate is indicated for the treatment or prevention of bronchospasm in adults, adolescents, and children 6 years of age and older with reversible obstructive airway disease.

Launch Date

1999
Primary
XOPENEX

Approved Use

XOPENEX (levalbuterol HCl) Inhalation Solution Concentrate is indicated for the treatment or prevention of bronchospasm in adults, adolescents, and children 6 years of age and older with reversible obstructive airway disease.

Launch Date

1999
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
199 pg/mL
90 μg single, respiratory
dose: 90 μg
route of administration: Respiratory
experiment type: SINGLE
co-administered:
LEVALBUTEROL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
238 pg/mL
180 μg single, respiratory
dose: 180 μg
route of administration: Respiratory
experiment type: SINGLE
co-administered:
LEVALBUTEROL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
4.5 ng/mL
1.25 mg 4 times / 2 hours multiple, respiratory
dose: 1.25 mg
route of administration: Respiratory
experiment type: MULTIPLE
co-administered:
LEVALBUTEROL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
1.1 ng/mL
1.25 mg single, respiratory
dose: 1.25 mg
route of administration: Respiratory
experiment type: SINGLE
co-administered:
LEVALBUTEROL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
163 pg/mL
90 μg single, respiratory
dose: 90 μg
route of administration: Respiratory
experiment type: SINGLE
co-administered:
LEVALBUTEROL plasma
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: UNKNOWN
food status: UNKNOWN
238 pg/mL
180 μg single, respiratory
dose: 180 μg
route of administration: Respiratory
experiment type: SINGLE
co-administered:
LEVALBUTEROL plasma
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: UNKNOWN
food status: UNKNOWN
0.303 ng/mL
0.31 mg single, respiratory
dose: 0.31 mg
route of administration: Respiratory
experiment type: SINGLE
co-administered:
LEVALBUTEROL plasma
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: UNKNOWN
food status: UNKNOWN
0.521 ng/mL
0.63 mg single, respiratory
dose: 0.63 mg
route of administration: Respiratory
experiment type: SINGLE
co-administered:
LEVALBUTEROL plasma
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
695 pg × h/mL
90 μg single, respiratory
dose: 90 μg
route of administration: Respiratory
experiment type: SINGLE
co-administered:
LEVALBUTEROL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
798 pg × h/mL
180 μg single, respiratory
dose: 180 μg
route of administration: Respiratory
experiment type: SINGLE
co-administered:
LEVALBUTEROL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
17.4 ng × h/mL
1.25 mg 4 times / 2 hours multiple, respiratory
dose: 1.25 mg
route of administration: Respiratory
experiment type: MULTIPLE
co-administered:
LEVALBUTEROL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
3.3 ng × h/mL
1.25 mg single, respiratory
dose: 1.25 mg
route of administration: Respiratory
experiment type: SINGLE
co-administered:
LEVALBUTEROL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
579 pg × h/mL
90 μg single, respiratory
dose: 90 μg
route of administration: Respiratory
experiment type: SINGLE
co-administered:
LEVALBUTEROL plasma
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: UNKNOWN
food status: UNKNOWN
828 pg × h/mL
180 μg single, respiratory
dose: 180 μg
route of administration: Respiratory
experiment type: SINGLE
co-administered:
LEVALBUTEROL plasma
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: UNKNOWN
food status: UNKNOWN
1.36 ng × h/mL
0.31 mg single, respiratory
dose: 0.31 mg
route of administration: Respiratory
experiment type: SINGLE
co-administered:
LEVALBUTEROL plasma
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: UNKNOWN
food status: UNKNOWN
2.55 ng × h/mL
0.63 mg single, respiratory
dose: 0.63 mg
route of administration: Respiratory
experiment type: SINGLE
co-administered:
LEVALBUTEROL plasma
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
4 h
1.25 mg 4 times / 2 hours multiple, respiratory
dose: 1.25 mg
route of administration: Respiratory
experiment type: MULTIPLE
co-administered:
LEVALBUTEROL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
3.3 h
1.25 mg single, respiratory
dose: 1.25 mg
route of administration: Respiratory
experiment type: SINGLE
co-administered:
LEVALBUTEROL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
90.55%
LEVALBUTEROL plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
90 ug 1 times / day steady, respiratory
Recommended
Dose: 90 ug, 1 times / day
Route: respiratory
Route: steady
Dose: 90 ug, 1 times / day
Sources:
unhealthy, 4 - 11 years
n = 76
Health Status: unhealthy
Condition: Asthma
Age Group: 4 - 11 years
Sex: M+F
Population Size: 76
Sources:
Disc. AE: Asthma...
AEs leading to
discontinuation/dose reduction:
Asthma (1 patient)
Sources:
90 ug 4 times / day steady, respiratory
Studied dose
Dose: 90 ug, 4 times / day
Route: respiratory
Route: steady
Dose: 90 ug, 4 times / day
Sources:
unhealthy, > 12 years
n = 496
Health Status: unhealthy
Condition: Asthma
Age Group: > 12 years
Sex: M+F
Population Size: 496
Sources:
Disc. AE: Bronchitis, Dyspnea...
Other AEs: Apparent life threatening event, Bronchitis...
AEs leading to
discontinuation/dose reduction:
Bronchitis (45 patients)
Dyspnea (45 patients)
Lung disorder (45 patients)
Other AEs:
Apparent life threatening event (18 patients)
Bronchitis (131 patient)
Dyspnea (131 patient)
Lung disorder (131 patient)
Tachycardia (67 patients)
Palpitation (67 patients)
Chest pain (67 patients)
Arrhythmia (67 patients)
Hypertension (67 patients)
Dyspepsia (67 patients)
Nausea (67 patients)
Leg cramps (67 patients)
Sources:
AEs

AEs

AESignificanceDosePopulation
Asthma 1 patient
Disc. AE
90 ug 1 times / day steady, respiratory
Recommended
Dose: 90 ug, 1 times / day
Route: respiratory
Route: steady
Dose: 90 ug, 1 times / day
Sources:
unhealthy, 4 - 11 years
n = 76
Health Status: unhealthy
Condition: Asthma
Age Group: 4 - 11 years
Sex: M+F
Population Size: 76
Sources:
Bronchitis 131 patient
90 ug 4 times / day steady, respiratory
Studied dose
Dose: 90 ug, 4 times / day
Route: respiratory
Route: steady
Dose: 90 ug, 4 times / day
Sources:
unhealthy, > 12 years
n = 496
Health Status: unhealthy
Condition: Asthma
Age Group: > 12 years
Sex: M+F
Population Size: 496
Sources:
Dyspnea 131 patient
90 ug 4 times / day steady, respiratory
Studied dose
Dose: 90 ug, 4 times / day
Route: respiratory
Route: steady
Dose: 90 ug, 4 times / day
Sources:
unhealthy, > 12 years
n = 496
Health Status: unhealthy
Condition: Asthma
Age Group: > 12 years
Sex: M+F
Population Size: 496
Sources:
Lung disorder 131 patient
90 ug 4 times / day steady, respiratory
Studied dose
Dose: 90 ug, 4 times / day
Route: respiratory
Route: steady
Dose: 90 ug, 4 times / day
Sources:
unhealthy, > 12 years
n = 496
Health Status: unhealthy
Condition: Asthma
Age Group: > 12 years
Sex: M+F
Population Size: 496
Sources:
Apparent life threatening event 18 patients
90 ug 4 times / day steady, respiratory
Studied dose
Dose: 90 ug, 4 times / day
Route: respiratory
Route: steady
Dose: 90 ug, 4 times / day
Sources:
unhealthy, > 12 years
n = 496
Health Status: unhealthy
Condition: Asthma
Age Group: > 12 years
Sex: M+F
Population Size: 496
Sources:
Bronchitis 45 patients
Disc. AE
90 ug 4 times / day steady, respiratory
Studied dose
Dose: 90 ug, 4 times / day
Route: respiratory
Route: steady
Dose: 90 ug, 4 times / day
Sources:
unhealthy, > 12 years
n = 496
Health Status: unhealthy
Condition: Asthma
Age Group: > 12 years
Sex: M+F
Population Size: 496
Sources:
Dyspnea 45 patients
Disc. AE
90 ug 4 times / day steady, respiratory
Studied dose
Dose: 90 ug, 4 times / day
Route: respiratory
Route: steady
Dose: 90 ug, 4 times / day
Sources:
unhealthy, > 12 years
n = 496
Health Status: unhealthy
Condition: Asthma
Age Group: > 12 years
Sex: M+F
Population Size: 496
Sources:
Lung disorder 45 patients
Disc. AE
90 ug 4 times / day steady, respiratory
Studied dose
Dose: 90 ug, 4 times / day
Route: respiratory
Route: steady
Dose: 90 ug, 4 times / day
Sources:
unhealthy, > 12 years
n = 496
Health Status: unhealthy
Condition: Asthma
Age Group: > 12 years
Sex: M+F
Population Size: 496
Sources:
Arrhythmia 67 patients
90 ug 4 times / day steady, respiratory
Studied dose
Dose: 90 ug, 4 times / day
Route: respiratory
Route: steady
Dose: 90 ug, 4 times / day
Sources:
unhealthy, > 12 years
n = 496
Health Status: unhealthy
Condition: Asthma
Age Group: > 12 years
Sex: M+F
Population Size: 496
Sources:
Chest pain 67 patients
90 ug 4 times / day steady, respiratory
Studied dose
Dose: 90 ug, 4 times / day
Route: respiratory
Route: steady
Dose: 90 ug, 4 times / day
Sources:
unhealthy, > 12 years
n = 496
Health Status: unhealthy
Condition: Asthma
Age Group: > 12 years
Sex: M+F
Population Size: 496
Sources:
Dyspepsia 67 patients
90 ug 4 times / day steady, respiratory
Studied dose
Dose: 90 ug, 4 times / day
Route: respiratory
Route: steady
Dose: 90 ug, 4 times / day
Sources:
unhealthy, > 12 years
n = 496
Health Status: unhealthy
Condition: Asthma
Age Group: > 12 years
Sex: M+F
Population Size: 496
Sources:
Hypertension 67 patients
90 ug 4 times / day steady, respiratory
Studied dose
Dose: 90 ug, 4 times / day
Route: respiratory
Route: steady
Dose: 90 ug, 4 times / day
Sources:
unhealthy, > 12 years
n = 496
Health Status: unhealthy
Condition: Asthma
Age Group: > 12 years
Sex: M+F
Population Size: 496
Sources:
Leg cramps 67 patients
90 ug 4 times / day steady, respiratory
Studied dose
Dose: 90 ug, 4 times / day
Route: respiratory
Route: steady
Dose: 90 ug, 4 times / day
Sources:
unhealthy, > 12 years
n = 496
Health Status: unhealthy
Condition: Asthma
Age Group: > 12 years
Sex: M+F
Population Size: 496
Sources:
Nausea 67 patients
90 ug 4 times / day steady, respiratory
Studied dose
Dose: 90 ug, 4 times / day
Route: respiratory
Route: steady
Dose: 90 ug, 4 times / day
Sources:
unhealthy, > 12 years
n = 496
Health Status: unhealthy
Condition: Asthma
Age Group: > 12 years
Sex: M+F
Population Size: 496
Sources:
Palpitation 67 patients
90 ug 4 times / day steady, respiratory
Studied dose
Dose: 90 ug, 4 times / day
Route: respiratory
Route: steady
Dose: 90 ug, 4 times / day
Sources:
unhealthy, > 12 years
n = 496
Health Status: unhealthy
Condition: Asthma
Age Group: > 12 years
Sex: M+F
Population Size: 496
Sources:
Tachycardia 67 patients
90 ug 4 times / day steady, respiratory
Studied dose
Dose: 90 ug, 4 times / day
Route: respiratory
Route: steady
Dose: 90 ug, 4 times / day
Sources:
unhealthy, > 12 years
n = 496
Health Status: unhealthy
Condition: Asthma
Age Group: > 12 years
Sex: M+F
Population Size: 496
Sources:
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Comparison of innovator and generic salbutamol inhalers: a double-blind randomized study of efficacy and tolerance.
2002
The effect of alkylpolyglycoside surfactants on the crystallization of spray-dried salbutamol sulphate: a GravimetricNear-Infrared Spectroscopy Study.
2002
Levalbuterol has not been established to have therapeutic advantage over racemic albuterol.
2002 Aug
Apparent ELISA detection times for albuterol after administration with the torpex equine inhaler device.
2002 Fall
Bronchodilating effects of salbutamol from a novel inhaler Airmax.
2002 Jul
Application of the chiral acyl anion equivalent, trans-1,3-dithiane 1,3-dioxide, to an asymmetric synthesis of (R)-salbutamol.
2002 Nov 29
Particle interactions involved in aerosol dispersion of ternary interactive mixtures.
2002 Oct
The influence of relative humidity on particulate interactions in carrier-based dry powder inhaler formulations.
2002 Oct 10
Effect of levalbuterol on prehospital patient parameters.
2002 Sep
Influence of excipients, drugs, and osmotic agent in the inner core on the time-controlled disintegration of compression-coated ethylcellulose tablets.
2002 Sep
Novolizer: a multidose dry powder inhaler.
2003
Investigation of processing parameters of spray freezing into liquid to prepare polyethylene glycol polymeric particles for drug delivery.
2003
Salbutamol sulfate suppositories: influence of formulation on physical parameters and stability.
2003
Investigation into the effect of humidity on drug-drug interactions using the atomic force microscope.
2003 Apr
Comparison of racemic albuterol and levalbuterol for treatment of acute asthma.
2003 Dec
Mirror images: is levalbuterol the fairest of them all?
2003 Dec
Effect of surface covering of lactose carrier particles on dry powder inhalation properties of salbutamol sulfate.
2003 Dec
Prospective observational cohort safety study to monitor the introduction of a non-CFC formulation of salbutamol with HFA134a in England.
2003 Feb
Influence of physico-chemical carrier properties on the in vitro aerosol deposition from interactive mixtures.
2003 Feb 18
Metabolism of salbutamol differs between asthmatic patients and healthy volunteers.
2003 Jan
Levalbuterol compared to racemic albuterol: efficacy and outcomes in patients hospitalized with COPD or asthma.
2003 Jan
Preparation of dry powder inhalation by surface treatment of lactose carrier particles.
2003 Jan
Planar gamma scintigraphy--points to consider when quantifying pulmonary dry powder aerosol deposition.
2003 Jan 30
Characterisation and deposition studies of engineered lactose crystals with potential for use as a carrier for aerosolised salbutamol sulfate from dry powder inhalers.
2003 Jul
Levalbuterol is as effective as racemic albuterol in lowering serum potassium.
2003 Jul
Three useful bromimetric methods for the determination of salbutamol sulfate.
2003 Jul
Self-hypnosis for anxiety associated with severe asthma: a case report.
2003 Jul 22
Albuterol improves response to levodopa and increases skeletal muscle mass in patients with fluctuating Parkinson disease.
2003 Jul-Aug
Levalbuterol: pharmacologic properties and use in the treatment of pediatric and adult asthma.
2003 Jun
Levalbuterol toxicity: no reason to be jittery.
2003 Jun
(R,S)-salbutamol plasma concentrations in severe asthma.
2003 Jun
Planar gamma scintigraphy--points to consider when quantifying pulmonary dry powder aerosol deposition.
2003 Jun 4
Characterization of particle-interactions by atomic force microscopy: effect of contact area.
2003 Mar
Single-isomer levalbuterol: a review of the acute data.
2003 Mar
A system for the production and delivery of monodisperse salbutamol aerosols to the lungs.
2003 Mar 26
Immobilization of fine particles on lactose carrier by precision coating and its effect on the performance of dry powder formulations.
2003 May
The influence of carrier and drug morphology on drug delivery from dry powder formulations.
2003 May 12
Influence of mechanical activation on the physical stability of salbutamol sulphate.
2003 Nov
Effect of humidity on aerosolization of micronized drugs.
2003 Oct
A meta-analysis of randomized controlled trials evaluating the efficacy of epinephrine for the treatment of acute viral bronchiolitis.
2003 Oct
Albuterol aerosol delivered via metered-dose inhaler to intubated pediatric models of 3 ages, with 4 spacer designs.
2003 Oct
Changes in heart rate associated with nebulized racemic albuterol and levalbuterol in intensive care patients.
2003 Oct 1
Investigation of the physical properties of spray-dried stabilised lysozyme particles.
2003 Sep
Management of the acute exacerbation of asthma.
2003 Sep
Levalbuterol is not more cost-effective than albuterol for COPD.
2003 Sep
Levalbuterol vs racemic albuterol: science or drug company propaganda?
2003 Sep
An evaluation of nebulized levalbuterol in stable COPD.
2003 Sep
Urgent adenotonsillectomy: an analysis of risk factors associated with postoperative respiratory morbidity.
2003 Sep
Effects of carriers and storage of formulation on the lung deposition of a hydrophobic and hydrophilic drug from a DPI.
2003 Sep 16
Retrospective comparison of nebulized levalbuterol and albuterol for adverse events in patients with acute airflow obstruction.
2003 Sep-Oct
Patents

Patents

Sample Use Guides

Children 6–11 years old: The recommended dosage of Xopenex (levalbuterol HCl) Inhalation Solution for patients 6–11 years old is 0.31 mg administered three times a day, by nebulization. Routine dosing should not exceed 0.63 mg three times a day. Adults and Adolescents ≥12 years old: The recommended starting dosage of Xopenex (levalbuterol HCl) Inhalation Solution for patients 12 years of age and older is 0.63 mg administered three times a day, every 6 to 8 hours, by nebulization.
Route of Administration: Respiratory
In Vitro Use Guide
Curator's Comment: Levalbuterol inhibits cell growth by activating the cAMP/PKA pathway and inhibiting PI-3 kinase, NF-kappaB and Rb protein expression
Unknown
Substance Class Chemical
Created
by admin
on Sat Dec 16 04:53:40 GMT 2023
Edited
by admin
on Sat Dec 16 04:53:40 GMT 2023
Record UNII
ADS4I3E22M
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
LEVALBUTEROL TARTRATE
ORANGE BOOK   USAN  
USAN  
Official Name English
Levosalbutamol tartrate [WHO-DD]
Common Name English
LEVALBUTEROL TARTRATE [ORANGE BOOK]
Common Name English
LEVOSALBUTAMOL TARTRATE [MART.]
Common Name English
LEVOSALBUTAMOL TARTRATE
MART.   WHO-DD  
Common Name English
XOPENEX HFA
Brand Name English
1,3-BENZENEDIMETHANOL, .ALPHA.(SUP 1)-(((1,1-DIMETHYLETHYL)AMINO)METHYL)-4-HYDROXY-, (.ALPHA.(SUP 1)R)-, (2R,3R)-2,3-DIHYDROXYBUTANEDIOATE (2:1) (SALT)
Common Name English
LEVALBUTEROL TARTRATE [USAN]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C48149
Created by admin on Sat Dec 16 04:53:41 GMT 2023 , Edited by admin on Sat Dec 16 04:53:41 GMT 2023
NCI_THESAURUS C319
Created by admin on Sat Dec 16 04:53:41 GMT 2023 , Edited by admin on Sat Dec 16 04:53:41 GMT 2023
Code System Code Type Description
RXCUI
487066
Created by admin on Sat Dec 16 04:53:41 GMT 2023 , Edited by admin on Sat Dec 16 04:53:41 GMT 2023
PRIMARY RxNorm
ChEMBL
CHEMBL1002
Created by admin on Sat Dec 16 04:53:41 GMT 2023 , Edited by admin on Sat Dec 16 04:53:41 GMT 2023
PRIMARY
USAN
QQ-74
Created by admin on Sat Dec 16 04:53:41 GMT 2023 , Edited by admin on Sat Dec 16 04:53:41 GMT 2023
PRIMARY
NCI_THESAURUS
C66003
Created by admin on Sat Dec 16 04:53:41 GMT 2023 , Edited by admin on Sat Dec 16 04:53:41 GMT 2023
PRIMARY
CAS
661464-94-4
Created by admin on Sat Dec 16 04:53:41 GMT 2023 , Edited by admin on Sat Dec 16 04:53:41 GMT 2023
PRIMARY
DAILYMED
ADS4I3E22M
Created by admin on Sat Dec 16 04:53:41 GMT 2023 , Edited by admin on Sat Dec 16 04:53:41 GMT 2023
PRIMARY
PUBCHEM
10349032
Created by admin on Sat Dec 16 04:53:41 GMT 2023 , Edited by admin on Sat Dec 16 04:53:41 GMT 2023
PRIMARY
SMS_ID
100000087598
Created by admin on Sat Dec 16 04:53:41 GMT 2023 , Edited by admin on Sat Dec 16 04:53:41 GMT 2023
PRIMARY
EVMPD
SUB23347
Created by admin on Sat Dec 16 04:53:41 GMT 2023 , Edited by admin on Sat Dec 16 04:53:41 GMT 2023
PRIMARY
DRUG BANK
DBSALT001385
Created by admin on Sat Dec 16 04:53:41 GMT 2023 , Edited by admin on Sat Dec 16 04:53:41 GMT 2023
PRIMARY
EPA CompTox
DTXSID10984620
Created by admin on Sat Dec 16 04:53:41 GMT 2023 , Edited by admin on Sat Dec 16 04:53:41 GMT 2023
PRIMARY
FDA UNII
ADS4I3E22M
Created by admin on Sat Dec 16 04:53:41 GMT 2023 , Edited by admin on Sat Dec 16 04:53:41 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY